These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23328800)

  • 1. Patterns of adherence behaviour for patients with glaucoma.
    Cate H; Bhattacharya D; Clark A; Holland R; Broadway DC
    Eye (Lond); 2013 Apr; 27(4):545-53. PubMed ID: 23328800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving adherence to glaucoma medication: a randomised controlled trial of a patient-centred intervention (The Norwich Adherence Glaucoma Study).
    Cate H; Bhattacharya D; Clark A; Fordham R; Holland R; Broadway DC
    BMC Ophthalmol; 2014 Mar; 14():32. PubMed ID: 24655814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid.
    Ajit RR; Fenerty CH; Henson DB
    Eye (Lond); 2010 Aug; 24(8):1338-43. PubMed ID: 20339390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for a randomised controlled trial to estimate the effects and costs of a patient centred educational intervention in glaucoma management.
    Cate H; Bhattacharya D; Clark A; Fordham R; Notley C; Broadway DC
    BMC Ophthalmol; 2012 Nov; 12():57. PubMed ID: 23171166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination.
    Rossi GC; Pasinetti GM; Scudeller L; Tinelli C; Milano G; Bianchi PE
    Expert Opin Pharmacother; 2010 Mar; 11(4):499-504. PubMed ID: 20163264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of measures used to describe adherence to glaucoma medication in a randomised controlled trial.
    Cate H; Bhattacharya D; Clark A; Holland R; Broadway DC
    Clin Trials; 2015 Dec; 12(6):608-17. PubMed ID: 26183437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence with prostaglandin agonist use with and without adjunctive therapy for glaucoma patients: a Canadian population-based analysis.
    Iskedjian M; Covert DW; Walker JH
    Patient; 2011; 4(2):133-41. PubMed ID: 21766903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma.
    Friedman DS; Okeke CO; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Quigley HA
    Ophthalmology; 2009 Jun; 116(6):1097-105. PubMed ID: 19376591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study.
    Okeke CO; Quigley HA; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Friedman DS
    Ophthalmology; 2009 Feb; 116(2):191-9. PubMed ID: 19084273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.
    Schwartz GF; Tan J; Kotak S
    J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do adherence rates and glaucomatous visual field progression correlate?
    Rossi GC; Pasinetti GM; Scudeller L; Radaelli R; Bianchi PE
    Eur J Ophthalmol; 2011; 21(4):410-4. PubMed ID: 21140373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence improvement in Dutch glaucoma patients: a randomized controlled trial.
    Beckers HJ; Webers CA; Busch MJ; Brink HM; Colen TP; Schouten JS;
    Acta Ophthalmol; 2013 Nov; 91(7):610-8. PubMed ID: 23025424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension.
    Flowers B; Wand M; Piltz-Seymour J; Berke SJ; Day D; Teague J; Smoot TM; Landry TA; Bergamini MV; Mallick S;
    Clin Ther; 2006 Nov; 28(11):1803-11. PubMed ID: 17213000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the role of travoprost 0.004% ophthalmic solution in the management of open angle glaucoma and ocular hypertensive patients.
    Chiselită D;
    Oftalmologia; 2007; 51(2):81-6. PubMed ID: 17937041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients.
    Okeke CO; Quigley HA; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Friedman DS
    Ophthalmology; 2009 Dec; 116(12):2286-93. PubMed ID: 19815286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure.
    Dubiner HB; Sircy MD; Landry T; Bergamini MV; Silver LH; Darell Turner F; Robertson S; Andrew RM; Weiner A; Przydryga J
    Clin Ther; 2004 Jan; 26(1):84-91. PubMed ID: 14996520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
    Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France.
    Payet S; Denis P; Berdeaux G; Launois R
    Clin Drug Investig; 2008; 28(3):183-98. PubMed ID: 18266403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personality traits, depression, and objectively measured adherence to once-daily prostaglandin analog medication in glaucoma.
    Holló G; Kóthy P; Géczy A; Vargha P
    J Glaucoma; 2009; 18(4):288-92. PubMed ID: 19365193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.